

Ad-hoc-Mitteilung nach Art. 17 Marktmissbrauchsverordnung

Darwin Group enters into supply agreement for genetic testing and nutritional supplements with Cardone Ventures LLC

München, April 2nd.,2024

Darwin Group enters into supply agreement for genetic testing and nutritional supplements with Cardone Ventures LLC

Novogenia GmbH, a wholly owned subsidiary of Darwin AG, has concluded a contract with Cardone Ventures LLC for the supply of genetic test kits and associated evaluations as well as another contract for the supply of nutritional supplements. The products and services are sold under the 10X Health brand.

The sales volumes forecast in the contract over a term of 10 years would have a significant effect on Darwin Group's asset, financial and, in particular, earnings situation provided that orders will be made by Cardone Ventures. Since at least the forecast sales volumes for the first year of cooperation are guaranteed, it is very likely that a corresponding significant effect on the asset, financial and earnings situation will actually occur.

The parties have contractually agreed not to disclose the exact sales volumes and prices. However, Novogenia GmbH assumes that the collaboration with Cardone Ventures / 10X Health will shape Novogenia GmbH's sales in the area of genetic test kits and analyzes as well as nutritional supplements in the foreseeable future and will lead to significantly positive margins.

About Darwin AG

The "Darwin Group" (i.e. Darwin AG including its subsidiaries and subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analyzes carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in

the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.

Contact:

Darwin AG
Brienner Str. 7
80333 Munich
Tel: +49 89 / 20 500 450
investor.relations@darwin-biotech.com